Krka, Accord And Xeris Pick Up European Nods
Rivals To Revlimid And Sutent Accompanied By GlucaGen Hybrid
The EMA’s CHMP has recommended granting pan-European marketing authorizations for Krka’s lenalidomide versions of Revlimid and Accord’s sunitinib rival to Sutent, as well as Xeris Pharmaceuticals’ glucagon hybrid rival to Glucagen.
You may also be interested in...
After reporting a profitable 2020, Slovenia’s Krka is looking to expand its cardiovascular and oncology portfolio, while adding to its diabetes and central nervous system range as well. The firm has also started manufacturing in China for the local market.
Slovenia’s Krka saw business boom as it rushed to supply the demand created by the coronavirus pandemic, while reaping the benefits from its vertically integrated business model. CEO and president of the management board Jože Colarič has just been appointed for another six-year term.
Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.